How to Get Belsomra (Suvorexant) in Colorado

What Suvorexant Is and Why It Requires a Prescription

Suvorexant is a dual orexin receptor antagonist that blocks wake-promoting neuropeptides orexin-A and orexin-B. The FDA approved it in August 2014 as a Schedule IV controlled substance for insomnia characterized by difficulty with sleep onset or maintenance [1]. Because of its controlled status, obtaining suvorexant in Colorado requires a valid prescription from a DEA-registered provider.

In the key phase III trial by Herring et al. (N=1,021), suvorexant 40 mg and 20 mg significantly improved subjective total sleep time versus placebo at month 1 (difference: 22.4 minutes for 40 mg, P<0.001) and sustained benefit through month 3 [2]. The approved dose range (5 to 20 mg) was selected based on this efficacy data balanced against next-morning somnolence at higher doses. A separate 12-month safety study (N=521 on suvorexant vs. N=258 placebo) found no evidence of rebound insomnia upon discontinuation [3].

Unlike benzodiazepines or Z-drugs that modulate GABA receptors, suvorexant's orexin-blocking mechanism preserves normal sleep architecture. Polysomnography data from the registration trials showed increased REM and non-REM sleep without suppression of slow-wave sleep [2].

Who Can Prescribe Belsomra in Colorado

Any Colorado-licensed clinician with an active DEA registration and Schedule IV prescribing authority can write a suvorexant prescription. This includes physicians (MD/DO), nurse practitioners, and physician assistants.

Colorado grants NPs full practice authority under C.R.S. 12-255-112, meaning no collaborative agreement with a physician is needed after 3 to 600 hours of mentored practice. PAs prescribe under C.R.S. 12-240-132 with a delegation agreement but have independent Schedule IV authority within that scope. For patients seeking telehealth access, this means a wider pool of prescribers is available compared to states requiring physician-only controlled substance prescriptions.

The prescriber must conduct an initial evaluation. Per the American Academy of Sleep Medicine (AASM) clinical practice guideline on pharmacologic treatment of chronic insomnia (2017), this evaluation should include screening for obstructive sleep apnea, restless legs syndrome, and psychiatric comorbidities before initiating any hypnotic [4]. Colorado-specific statute does not mandate polysomnography before prescribing suvorexant, but insurers often require documentation of non-pharmacologic interventions (CBT-I attempt or contraindication) for prior authorization.

Telehealth Pathways for Colorado Residents

Colorado allows prescribing Schedule IV controlled substances via telehealth without requiring an initial in-person visit. The Ryan Haight Act exemption for telemedicine, made permanent through DEA rulemaking in 2025, permits providers registered in Colorado to prescribe suvorexant after a real-time audio-video consultation [5].

Patients connect with a licensed prescriber, complete a sleep history intake, and receive an electronic prescription sent directly to a Colorado pharmacy. The entire process from scheduling to having a prescription on file typically takes 24 to 72 hours for asynchronous-first platforms, or same-day for synchronous video visits.

Telehealth prescribers should document the following during the initial visit: duration of insomnia symptoms (at least 3 nights per week for at least 3 months meets chronic insomnia criteria per ICSD-3), prior treatments attempted, screening for narcolepsy or cataplexy (suvorexant is contraindicated in narcolepsy), and current medication list to assess CYP3A4 interactions [1]. Colorado's telehealth parity law (HB 19-1017) requires commercial insurers to reimburse telehealth visits at the same rate as in-person encounters, lowering cost barriers to the prescribing consultation.

Insurance Coverage and Prior Authorization in Colorado

Colorado Medicaid (Health First Colorado) does not cover suvorexant for insomnia. Coverage is restricted to the type 2 diabetes indication only, which is an off-label use that Medicaid has elected to include in its formulary while excluding the FDA-approved insomnia indication.

Commercial plans in Colorado (Anthem, Cigna, UnitedHealthcare, Kaiser Permanente Colorado) typically place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Prior authorization is standard. Documentation requirements generally include:

• Diagnosis of chronic insomnia disorder (ICD-10: G47.00 or F51.01)
• Trial and failure of, or contraindication to, at least one first-line agent (zolpidem, eszopiclone, or low-dose doxepin)
• Duration of insomnia symptoms (minimum 3 months)
• Documentation that CBT-I was offered or attempted, or a clinical reason it is inappropriate
• Prescriber attestation that the patient does not have narcolepsy

Turnaround for prior authorization in Colorado averages 3 to 5 business days for commercial plans. If denied, Colorado insurance regulations (3 CCR 702-4) entitle patients to an expedited external review within 72 hours for urgent cases.

Without insurance, Belsomra's average retail price in Colorado ranges from $380 to $420 for a 30-day supply. Merck's patient assistance program covers eligible uninsured patients with household income below 400% of the federal poverty level. Generic suvorexant became available in 2023 after patent expiration, bringing cash-pay pricing to approximately $45 to $90 per month at Colorado retail pharmacies.

503A Compounding Pharmacies in Colorado

Colorado licenses 503A compounding pharmacies through the State Board of Pharmacy under 3 CCR 719-1. These pharmacies can compound suvorexant into alternative formulations (oral suspensions, sublingual troches, or custom-dose capsules) when a prescriber determines that a commercially available dosage form does not meet the patient's clinical needs.

A valid patient-specific prescription is required. The prescriber must document a clinical rationale for compounding, such as dysphagia preventing tablet use, need for a dose between available strengths (e.g., 7.5 mg), or allergy to an inactive ingredient in the manufactured product. Colorado 503A pharmacies can ship within the state but cannot distribute across state lines without 503B outsourcing facility registration.

Compounded suvorexant is not covered by most insurance plans but typically costs $60 to $120 for a 30-day supply depending on dose and formulation. Patients should verify their pharmacy holds a current Colorado compounding license and conducts potency testing on each batch.

What Labs and Evaluations Are Needed Before Starting

No mandatory laboratory testing is required before prescribing suvorexant. The FDA label does not specify pre-treatment labs [1]. However, clinical best practice and insurer requirements may lead prescribers to order:

• Hepatic function panel: suvorexant is extensively metabolized by CYP3A4, and severe hepatic impairment increases exposure. The FDA label recommends caution and no dose adjustment studies exist for Child-Pugh C patients [1].
• Thyroid panel (TSH): to exclude hypothyroidism as a reversible cause of fatigue mimicking insomnia.
• Iron studies and ferritin: to screen for restless legs syndrome, which can present as sleep-onset difficulty.
• Home sleep apnea test or polysomnography: if the patient reports snoring, witnessed apneas, or has BMI above 30. The AASM recommends excluding OSA before initiating hypnotics [4].

These are not suvorexant-specific requirements but rather standard insomnia workup components that Colorado prescribers include to satisfy prior authorization documentation and rule out secondary causes.

Transferring an Existing Belsomra Prescription to Colorado

Colorado Board of Pharmacy rules (6 CCR 1011-1, Chapter 21) permit transfer of Schedule IV prescriptions between pharmacies. A patient moving to Colorado from another state can have their current pharmacy transfer remaining refills to a Colorado pharmacy via direct pharmacist-to-pharmacist communication.

The transfer must occur in real-time (phone or secure electronic system). The originating pharmacy records the transfer out, and the receiving Colorado pharmacy verifies the prescriber's DEA number, remaining refills, and original date written. Schedule IV prescriptions in Colorado allow up to 5 refills within 6 months of the original date written.

If the prescription has no remaining refills or has expired, the patient needs a new prescription from a Colorado-licensed provider. Telehealth makes this straightforward. The new prescriber will want records of the patient's current dose, treatment duration, and efficacy to continue therapy without an unnecessary re-titration period.

Timeline: From First Visit to Medication in Hand

Most Colorado patients complete the process in 3 to 7 days:

• Day 1: Telehealth or in-person consultation. Prescriber evaluates, confirms diagnosis, and submits e-prescription.
• Days 1 to 2: Pharmacy receives prescription. If no prior authorization needed (generic, or plan does not require PA), pharmacy fills same-day or next business day.
• Days 2 to 5: If prior authorization is required, pharmacy initiates PA request. Prescriber's office responds to insurer queries.
• Days 3 to 7: PA approved, prescription filled, patient picks up or receives mail delivery.

Expedited scenarios exist. Patients paying cash for generic suvorexant at a retail pharmacy can have medication in hand within hours of the prescribing visit. Mail-order pharmacies add 2 to 3 shipping days but often offer lower per-unit pricing.

Dosing and Safety Considerations Specific to Colorado Prescribing

The recommended starting dose is 10 mg taken within 30 minutes of bedtime with at least 7 hours remaining before planned waking [1]. The dose may increase to 20 mg if 10 mg is tolerated but insufficiently effective. Colorado's high altitude (mean elevation 6,800 feet) does not appear in clinical literature as a factor affecting suvorexant pharmacokinetics, but prescribers should note that altitude-related sleep disturbance is common among new Colorado residents and may confound insomnia assessment.

Drug interactions requiring dose reduction to 5 mg include concurrent use of moderate CYP3A4 inhibitors (diltiazem, erythromycin, fluconazole, verapamil). Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) contraindicate suvorexant use [1]. Colorado prescribers should specifically ask about fluconazole, as Valley fever (coccidioidomycosis) treatment occasionally occurs in patients with travel history to endemic regions.

The most common adverse effects in clinical trials were somnolence (7% vs. 3% placebo), headache, and dizziness [1]. Complex sleep behaviors (sleepwalking, sleep-driving) are a boxed warning shared across all orexin antagonists; the incidence was rare (<1%) in premarketing trials but the FDA added the warning in 2019 based on post-marketing reports across the DORA class [6].

How Suvorexant Compares to Other Colorado-Available Sleep Medications

Colorado prescribers have access to three FDA-approved DORAs: suvorexant (Belsomra), lemborexant (Dayvigo), and the newest entry, a low-dose DORA formulation. Head-to-head data remain limited, but a network meta-analysis published in the Annals of Internal Medicine (2022, 16 RCTs, N=6,984) found that DORAs as a class produced a mean increase of 22 to 28 minutes in total sleep time versus placebo, with no statistically significant difference in efficacy between suvorexant and lemborexant at their approved doses [7].

Compared to zolpidem (the most-prescribed hypnotic in Colorado), suvorexant carries lower abuse potential. A human abuse-liability study (N=36) showed that suvorexant 40 mg (twice the maximum approved dose) produced lower "drug liking" scores than zolpidem 30 mg (P<0.05) [8]. This profile makes suvorexant preferable for patients with a history of substance use disorder, a consideration relevant in Colorado given the state's above-average rates of polysubstance use.

For Colorado Medicaid patients who cannot access suvorexant for insomnia, alternatives on the preferred drug list include generic zolpidem (immediate and extended-release), trazodone (off-label), and doxepin 3 mg and 6 mg (Silenor).